NS Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

Continue Learn More X

Home » News » AngioDynamics’ DIRECT clinical study receives IRB approval for treating stage III pancreatic cancer » MDPR1

AngioDynamics’ DIRECT clinical study receives IRB approval for treating stage III pancreatic cancer

Image: AngioDynamics’ DIRECT clinical study receives IRB approval for treating stage III pancreatic cancer. Photo: Courtesy of rajcreationzs/FreeDigitalPhotos.net

NS Medical Devices is using cookies

Image: AngioDynamics’ DIRECT clinical study receives IRB approval for treating stage III pancreatic cancer. Photo: Courtesy of rajcreationzs/FreeDigitalPhotos.net

Related Article

Biggest players in the global wound care market

RECOMMENDED COMPANIES

MOST READ

Labcorp rolls out new blood-based test to early detect neurodegenerative diseases

3D Systems secures FDA approval for VSP PEEK Cranial Implant

TELA Bio launches OviTex IHR surgical mesh for inguinal hernia repair in US

Vivasure treats first patient with PerQseal Elite vascular closure system

Adherium secures FDA nod for Hailie Smartinhaler for COPD, Asthma

Recommended Whitepaper